Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $87 from $94 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $80 from $96 at Evercore ISI
- Boston Scientific Investors File Lawsuit Over Alleged Misleading Statements About Electrophysiology Business Growth
- AI Models Turn More Positive on Boston Scientific, But Weak Technicals Temper Enthusiasm
- FTC issued Second Request to Penumbra, Boston Scientific over merger review
- Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane